LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Listă Acțiuni・Erasca Inc

Erasca Inc

Închisă

13.4 4.44

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

12.22

Maxim

13.41

Indicatori cheie
By Trading Economics
Venit	-154M -183M
EPS	-0.6
Angajați	103
EBITDA	-5.3M -37M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+63.17% upside

Dividende
By Dow Jones
Următoarele câștiguri	10 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	476M 3.7B
Deschiderea anterioară	8.96
Închiderea anterioară	13.4

Erasca Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 iun. 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 iun. 2026, 23:45 UTC

Achiziții, Fuziuni, Preluări

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 iun. 2026, 23:44 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 iun. 2026, 23:43 UTC

Achiziții, Fuziuni, Preluări

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 iun. 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 iun. 2026, 22:06 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 iun. 2026, 22:05 UTC

Achiziții, Fuziuni, Preluări

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 iun. 2026, 20:51 UTC

Câștiguri

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 iun. 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 iun. 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 iun. 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 iun. 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 iun. 2026, 18:52 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 iun. 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 iun. 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 iun. 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 iun. 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 iun. 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 iun. 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iun. 2026, 16:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

9 iun. 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 iun. 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparație

Modificare preț

Erasca Inc Așteptări

Obiectiv de preț

By TipRanks

63.17% sus

Prognoză pe 12 luni

Medie 21 USD 63.17%

Maxim 30 USD

Minim 12 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruErasca Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor Erasca Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.